---
title: "Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration"
description: "Formulary evidence on Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration. Clinical evidence covers NORSE TWO, NORSE EIGHT, NORSE ONE, NORSE THREE, and NORSE SEVEN. 220 evidence topics quoted from 50 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration"
published: "2026-09-28T12:24:10-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Bevacizumab-vikg

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Neovascular age-related macular degeneration

<a id="topic-1.1.1-1"></a>

##### Summary

Nearly 20 million U.S. adults live with some form of age-related macular degeneration (AMD). Wet AMD accounts for approximately 10% of AMD cases but is responsible for 90% of legal blindness attributable to AMD. Global AMD prevalence was estimated at 196 million people in 2020, projected to increase to 288 million by 2040. In a U.S. claims analysis, the estimated annual all-cause cost for a patient with neovascular AMD (nAMD) was $24,520, and global estimates place the cost of visual impairment due to AMD at $343 billion, including $255 billion in direct healthcare costs.

Source: [BrightFocus Foundation](https://www.brightfocus.org/macular/facts-figures/); [Huang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534605/); [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Bevacizumab-vikg Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: pivotal and confirmatory trial results

Bevacizumab-vikg (Lytenava) is a vascular endothelial growth factor (VEGF) inhibitor formulated for intravitreal injection, dosed at 1.25 mg once monthly. In the pivotal phase 3 NORSE TWO trial, 41.7% of participants receiving bevacizumab-vikg (45 of 108 evaluable) gained 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters of best corrected visual acuity (BCVA) from baseline to Month 11, compared with 23.1% (24 of 104) receiving ranibizumab 0.5 mg dosed monthly for 3 months then quarterly (risk difference 0.1859, 95% CI 0.0442 to 0.3086). In the confirmatory NORSE EIGHT trial, 400 participants were randomized 1:1 to bevacizumab-vikg or monthly ranibizumab 0.5 mg for 3 doses; at Week 8, the primary endpoint of mean BCVA change did not meet its pre-specified non-inferiority margin of -3.5 letters (bevacizumab-vikg +3.3 letters versus ranibizumab +4.5 letters; least-squares mean difference -2.3, 95% CI -4.0 to -0.5), although bevacizumab-vikg showed a BCVA increase at Week 12 consistent with NORSE TWO. Across 601 participants in five clinical trials, the most common adverse reaction (occurring in 4% of participants) was conjunctival hemorrhage, compared with 3% for ranibizumab; eye pain and vitreous floaters each occurred in 2% of participants receiving bevacizumab-vikg compared with 1% for ranibizumab. Labeled warnings include endophthalmitis and retinal detachment, increases in intraocular pressure, and a potential risk of arterial thromboembolic events associated with VEGF inhibition.

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf); [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Bevacizumab-vikg

<a id="topic-1.1.3-1"></a>

##### Summary

No published cost-effectiveness analysis, budget impact model, or health technology assessment of bevacizumab-vikg has been identified. Outlook Therapeutics established a U.S. wholesale acquisition cost of $485 per vial on September 16, 2026. As of the report date, bevacizumab-vikg had not yet launched commercially in the United States; the company has stated it expects to make the product available to eligible patients before the end of calendar 2026 and has described the potential to exceed $500 million in annual U.S. sales by 2030.

Source: [Outlook Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/tm2625694d1_8k.htm); [Outlook Therapeutics third quarter fiscal year 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_ex99-1.htm); [Outlook Therapeutics FDA approval announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_ex99-1.htm)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

The FDA approved bevacizumab-vikg (Lytenava) on July 24, 2026, for neovascular (wet) age-related macular degeneration, after three Complete Response Letters and the addition of a second adequate and well-controlled trial (NORSE EIGHT) to the original NORSE TWO pivotal trial. It is the first FDA-approved ophthalmic formulation of bevacizumab, an antibody that has long been used off-label as a compounded, repackaged intravenous oncology product for wet AMD because of its comparatively low cost. Approval rests primarily on NORSE TWO, in which bevacizumab-vikg dosed monthly outperformed a less frequently dosed ranibizumab regimen on a visual-acuity-gain endpoint at 11 months, while the confirmatory NORSE EIGHT trial did not meet its pre-specified non-inferiority margin against monthly ranibizumab at Week 8, though the two arms converged by Week 12. No published budget impact model, ASP, or peer-reviewed NORSE EIGHT publication was identified as of the report date, and commercial launch, reimbursement coding, and real-world experience remain pending.

Source: [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf); [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf); [Outlook Therapeutics regulatory update (2023)](https://www.sec.gov/Archives/edgar/data/1649989/000110465923096669/tm2325118d1_ex99-1.htm); [Outlook Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm)

## Related pages
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: References](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: drug evaluation](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: new drug review](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses.md)
